[144] Avidity Biosciences, Inc. SEC Filing
Avidity Biosciences (RNA) filed a Form 144 reporting a proposed sale of 50,000 common shares to be executed through Morgan Stanley Smith Barney on 09/05/2025, with an aggregate market value of $2,423,500 based on the filing. The shares were acquired on 09/05/2025 by exercise of stock options and paid in cash. The filer also reported prior 10b5-1 sales of 25,000 shares on 08/28/2025 generating gross proceeds of $1,234,700. The filing includes the required representation that the seller is not aware of undisclosed material adverse information and references reliance on Rule 10b5-1 trading instructions where applicable.
Avidity Biosciences (RNA) ha presentato un Modulo 144 segnalando la proposta di vendita di 50.000 azioni ordinarie, da eseguirsi tramite Morgan Stanley Smith Barney il 09/05/2025, per un valore di mercato aggregato di $2.423.500 indicato nella comunicazione. Le azioni sono state acquisite il 09/05/2025 mediante esercizio di opzioni e pagate in contanti. Il dichiarante ha inoltre riportato precedenti vendite ai sensi della regola 10b5-1 di 25.000 azioni il 08/28/2025, che hanno generato proventi lordi di $1.234.700. Il filing include la dichiarazione richiesta che il venditore non 猫 a conoscenza di informazioni materiali avverse non divulgate e fa riferimento all'uso, se applicabile, di istruzioni di trading conformi alla Rule 10b5-1.
Avidity Biosciences (RNA) present贸 un Formulario 144 informando sobre la propuesta de venta de 50.000 acciones ordinarias, que se ejecutar铆a a trav茅s de Morgan Stanley Smith Barney el 09/05/2025, por un valor de mercado agregado de $2.423.500 seg煤n la presentaci贸n. Las acciones fueron adquiridas el 09/05/2025 mediante el ejercicio de opciones sobre acciones y pagadas en efectivo. El declarante tambi茅n inform贸 ventas previas bajo un plan 10b5-1 de 25.000 acciones el 08/28/2025, que generaron ingresos brutos de $1.234.700. La presentaci贸n incluye la representaci贸n requerida de que el vendedor no conoce informaci贸n material adversa no divulgada y menciona la dependencia, cuando corresponda, de instrucciones de negociaci贸n conforme a la Regla 10b5-1.
Avidity Biosciences (RNA)電� 鞝滌晥霅� 50,000 氤错喌欤� 毵る弰毳� 鞁犼碃頃橂姅 Form 144毳� 鞝滌稖頄堨溂氅�, 頃措嫻 毵る弰電� 09/05/2025鞐� Morgan Stanley Smith Barney毳� 韱淀暣 歆戫枆霅� 鞓堨爼鞚搓碃 鞝滌稖靹滌棎 霐半ジ 齑濎嫓鞛リ皜旃橂姅 $2,423,500鞛呺媹雼�. 頃措嫻 欤检嫕鞚� 09/05/2025鞐� 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑霅橃柎 顺勱笀鞙茧 歆�旮夒悩鞐堨姷雼堧嫟. 鞁犼碃鞛愲姅 霕愴暅 08/28/2025鞐� 鞁ろ枆霅� Rule 10b5-1鞐� 霐半ジ 鞚挫爠鞚� 25,000欤� 毵る弰搿� 齑� 靾橃澋 $1,234,700毳� 氚滌儩鞁滌及鞚岇潉 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 韺愲Г鞛愱皜 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 頃勳垬 歆勳垹鞚� 韽暔霅橃柎 鞛堨溂氅�, 頃措嫻霅橂姅 瓴届毎 Rule 10b5-1 瓯半灅 歆�旃棎 鞚橃〈頄堨潓鞚� 鞏戈笁頃橁碃 鞛堨姷雼堧嫟.
Avidity Biosciences (RNA) a d茅pos茅 un formulaire 144 signalant la vente propos茅e de 50 000 actions ordinaires, qui serait ex茅cut茅e par Morgan Stanley Smith Barney le 09/05/2025, pour une valeur de march茅 globale de $2 423 500 selon le d茅p么t. Les actions ont 茅t茅 acquises le 09/05/2025 par exercice d'options et pay茅es en 别蝉辫猫肠别蝉. Le d茅clarant a 茅galement indiqu茅 des ventes ant茅rieures au titre de la r猫gle 10b5-1 de 25 000 actions le 08/28/2025, g茅n茅rant un produit brut de $1 234 700. Le d茅p么t inclut la d茅claration requise selon laquelle le vendeur n'a pas connaissance d'informations d茅favorables mat茅rielles non divulgu茅es et mentionne, le cas 茅ch茅ant, le recours aux instructions de trading pr茅vues par la r猫gle 10b5-1.
Avidity Biosciences (RNA) reichte ein Formular 144 ein, in dem ein geplanter Verkauf von 50.000 Stammaktien gemeldet wird, der 眉ber Morgan Stanley Smith Barney am 09/05/2025 ausgef眉hrt werden soll, mit einem in der Meldung angegebenen aggregierten Marktwert von $2.423.500. Die Aktien wurden am 09/05/2025 durch Aus眉bung von Aktienoptionen erworben und in Bargeld bezahlt. Der Meldende gab au脽erdem fr眉here 10b5-1-Verk盲ufe von 25.000 Aktien am 08/28/2025 an, die Bruttoerl枚se von $1.234.700 erzielten. Die Einreichung enth盲lt die erforderliche Zusicherung, dass der Verk盲ufer nicht 眉ber nicht offengelegte wesentliche nachteilige Informationen Kenntnis hat, und verweist gegebenenfalls auf die Nutzung von Handelsanweisungen nach Rule 10b5-1.
- None.
- None.
Insights
TL;DR Routine insider sale following option exercise; modestly dilutive but likely non-material for investors.
The filing documents an insider or related person exercising options and proposing to sell 50,000 common shares valued at $2.42 million, executed through a broker on NASDAQ. The presence of prior 10b5-1 sales of 25,000 shares indicates a staged disposition plan rather than a single large block sale. This is standard compliance activity; the transaction increases free float but, given the issuer's reported outstanding shares of 128,653,337, the size is small relative to total equity and unlikely to materially affect market capitalization by itself.
TL;DR Disclosure appears complete for a Form 144; timing and 10b5-1 reference reduce governance concerns.
The filer disclosed acquisition details, nature of acquisition (option exercise), payment method, broker details and prior 10b5-1 sales, and included the statutory representation regarding material non-public information. These elements satisfy typical Rule 144 notice expectations and suggest adherence to insider trading protocols. No red flags such as unexplained transfers, gifts, or unusual counterparty arrangements are present in the disclosed fields.
Avidity Biosciences (RNA) ha presentato un Modulo 144 segnalando la proposta di vendita di 50.000 azioni ordinarie, da eseguirsi tramite Morgan Stanley Smith Barney il 09/05/2025, per un valore di mercato aggregato di $2.423.500 indicato nella comunicazione. Le azioni sono state acquisite il 09/05/2025 mediante esercizio di opzioni e pagate in contanti. Il dichiarante ha inoltre riportato precedenti vendite ai sensi della regola 10b5-1 di 25.000 azioni il 08/28/2025, che hanno generato proventi lordi di $1.234.700. Il filing include la dichiarazione richiesta che il venditore non 猫 a conoscenza di informazioni materiali avverse non divulgate e fa riferimento all'uso, se applicabile, di istruzioni di trading conformi alla Rule 10b5-1.
Avidity Biosciences (RNA) present贸 un Formulario 144 informando sobre la propuesta de venta de 50.000 acciones ordinarias, que se ejecutar铆a a trav茅s de Morgan Stanley Smith Barney el 09/05/2025, por un valor de mercado agregado de $2.423.500 seg煤n la presentaci贸n. Las acciones fueron adquiridas el 09/05/2025 mediante el ejercicio de opciones sobre acciones y pagadas en efectivo. El declarante tambi茅n inform贸 ventas previas bajo un plan 10b5-1 de 25.000 acciones el 08/28/2025, que generaron ingresos brutos de $1.234.700. La presentaci贸n incluye la representaci贸n requerida de que el vendedor no conoce informaci贸n material adversa no divulgada y menciona la dependencia, cuando corresponda, de instrucciones de negociaci贸n conforme a la Regla 10b5-1.
Avidity Biosciences (RNA)電� 鞝滌晥霅� 50,000 氤错喌欤� 毵る弰毳� 鞁犼碃頃橂姅 Form 144毳� 鞝滌稖頄堨溂氅�, 頃措嫻 毵る弰電� 09/05/2025鞐� Morgan Stanley Smith Barney毳� 韱淀暣 歆戫枆霅� 鞓堨爼鞚搓碃 鞝滌稖靹滌棎 霐半ジ 齑濎嫓鞛リ皜旃橂姅 $2,423,500鞛呺媹雼�. 頃措嫻 欤检嫕鞚� 09/05/2025鞐� 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑霅橃柎 顺勱笀鞙茧 歆�旮夒悩鞐堨姷雼堧嫟. 鞁犼碃鞛愲姅 霕愴暅 08/28/2025鞐� 鞁ろ枆霅� Rule 10b5-1鞐� 霐半ジ 鞚挫爠鞚� 25,000欤� 毵る弰搿� 齑� 靾橃澋 $1,234,700毳� 氚滌儩鞁滌及鞚岇潉 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 韺愲Г鞛愱皜 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 頃勳垬 歆勳垹鞚� 韽暔霅橃柎 鞛堨溂氅�, 頃措嫻霅橂姅 瓴届毎 Rule 10b5-1 瓯半灅 歆�旃棎 鞚橃〈頄堨潓鞚� 鞏戈笁頃橁碃 鞛堨姷雼堧嫟.
Avidity Biosciences (RNA) a d茅pos茅 un formulaire 144 signalant la vente propos茅e de 50 000 actions ordinaires, qui serait ex茅cut茅e par Morgan Stanley Smith Barney le 09/05/2025, pour une valeur de march茅 globale de $2 423 500 selon le d茅p么t. Les actions ont 茅t茅 acquises le 09/05/2025 par exercice d'options et pay茅es en 别蝉辫猫肠别蝉. Le d茅clarant a 茅galement indiqu茅 des ventes ant茅rieures au titre de la r猫gle 10b5-1 de 25 000 actions le 08/28/2025, g茅n茅rant un produit brut de $1 234 700. Le d茅p么t inclut la d茅claration requise selon laquelle le vendeur n'a pas connaissance d'informations d茅favorables mat茅rielles non divulgu茅es et mentionne, le cas 茅ch茅ant, le recours aux instructions de trading pr茅vues par la r猫gle 10b5-1.
Avidity Biosciences (RNA) reichte ein Formular 144 ein, in dem ein geplanter Verkauf von 50.000 Stammaktien gemeldet wird, der 眉ber Morgan Stanley Smith Barney am 09/05/2025 ausgef眉hrt werden soll, mit einem in der Meldung angegebenen aggregierten Marktwert von $2.423.500. Die Aktien wurden am 09/05/2025 durch Aus眉bung von Aktienoptionen erworben und in Bargeld bezahlt. Der Meldende gab au脽erdem fr眉here 10b5-1-Verk盲ufe von 25.000 Aktien am 08/28/2025 an, die Bruttoerl枚se von $1.234.700 erzielten. Die Einreichung enth盲lt die erforderliche Zusicherung, dass der Verk盲ufer nicht 眉ber nicht offengelegte wesentliche nachteilige Informationen Kenntnis hat, und verweist gegebenenfalls auf die Nutzung von Handelsanweisungen nach Rule 10b5-1.
FAQ
What did Avidity Biosciences (RNA) report on Form 144?
How were the 50,000 shares acquired according to the filing?
Were there any recent sales by the same person before this notice?
Through which broker will the proposed sale be executed?
Does the Form 144 include a statement about material non-public information?
